Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Tricida  (Stock symbol: TCDA )

7000 Shoreline Court, Suite 201
So. San Francisco, CA 94080
USA
(415) 429-7800
Website Company Summary Management Team
Management

CEO: Gerrit Klaerner (8/31/2013)
Finance: Geoffrey M. Parker (4/30/2017) ; Victoria Mapar (11/30/2017)
Technology: Wilhelm Stahl (2/28/2017)
General Counsel/Legal: Robert McKague
Board

Outside board: (May no longer be on the board) Kathryn Falberg (Jazz Pharmaceuticals Former CFO) David Hirsch (Longitude Capital Management Managing Director) David Bonita (OrbiMed Private Equity Partner) Robert J. Alpern (Yale School of Medicine Professor) Sandra I. Coufal (Sibling Capital Ventures President)
Former outside board: Klaus Veitinger (OrbiMed Venture Partner)
Company

Business description: Tricida, Inc. is an innovative startup company focused on the discovery and clinical development of novel therapeutics to address renal, metabolic and cardiovascular disease. Tricida is led by a management team with an accomplished and proven track record in discovering and developing new therapeutics, with extensive experience in building successful companies around strong science and unmet medical needs. The company is backed by world-class venture capital firms.
Capital

Rounds: 4
Recent Fundings: Nov 2017   Jul 2016
Capital raised: 157.0M
Last Round: 57.5M
Ownership: Public   Ipo Filing
Stock Symbol: TCDA
VCs include: Vivo Capital OrbiMed ;  Venrock Longitude Capital ;  Wellington Management Company ;  Sibling Capital Ventures ;  Limulus Venture Partners Cormorant Asset Management

Last Tweets


 

Last Mentions


Overview
Record updated: Mar 2020
Sector: Biotech
Year Founded: 2013
Headcount: 101-150 as of Mar 2020
Rounds: 4
Recent Fundings: Nov 2017   Jul 2016
Capital Raised: 157.0M
Last Round: 57.5M
Ownership: Public   Ipo Filing
Stock Symbol: TCDA